Literature DB >> 19632245

CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system.

Peimin Lu1, Cathy Gonzales, Yi Chen, Adedayo Adedoyin, Michele Hummel, Jeffrey D Kennedy, Garth T Whiteside.   

Abstract

AIMS: We sought to investigate effects of local and systemic inflammation on CNS permeability of small molecules and compare these to effects of direct injury to the nervous system. MAIN
METHODS: Evans blue was used to determine the integrity of the blood-brain barrier (BBB) following local inflammation, systemic inflammation, injury to the L5 spinal nerve or transient occlusion of the middle cerebral artery. In addition, three compounds having low, medium and high brain permeability (atenolol, morphine and oxycodone, respectively) were used. Following model establishment (4-hr post-carrageenan, 24-hr post-FCA, 2-, 4- and 24-hr post-LPS, 21 days post-nerve injury) compounds were administered and 30 min later the brain, spinal cord and blood removed. The plasma and tissue concentrations of compounds were quantified by LC/MS/MS. KEY
FINDINGS: Localized inflammation did not affect Evans blue penetration into the CNS but significantly increased morphine penetration into the spinal cord. Systemic inflammation increased the quantity of Evans blue in the CNS but also decreased the penetration of atenolol, morphine and oxycodone into the brain 4-hr post-insult. Nerve injury had no effect on Evans blue or compound penetration, while middle cerebral artery occlusion resulted in a large but short lived increase in Evans blue penetration into both the cortex and striatum. SIGNIFICANCE: The presence of inflammation may affect the CNS penetration of some compounds but is unlikely to lead to a large non-selective BBB breakdown. As a result, it is appropriate to test for side-effects, and conduct brain pharmacokinetic determinations, in naïve rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19632245     DOI: 10.1016/j.lfs.2009.07.009

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis.

Authors:  Cletus Cheyuo; Asha Jacob; Ping Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-11-08       Impact factor: 4.310

3.  Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury.

Authors:  Margarita Calvo; Ning Zhu; Christoforos Tsantoulas; Zhenzhong Ma; John Grist; Jeffrey A Loeb; David L H Bennett
Journal:  J Neurosci       Date:  2010-04-14       Impact factor: 6.167

4.  Tempol modulates changes in xenobiotic permeability and occludin oligomeric assemblies at the blood-brain barrier during inflammatory pain.

Authors:  Jeffrey J Lochhead; Gwen McCaffrey; Lucy Sanchez-Covarrubias; Jessica D Finch; Kristin M Demarco; Colleen E Quigley; Thomas P Davis; Patrick T Ronaldson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-11       Impact factor: 4.733

5.  Interactions between the immune and nervous systems in pain.

Authors:  Ke Ren; Ronald Dubner
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

Review 6.  A role for pericytes in chronic pain?

Authors:  Alexandra M Durrant; Matthew N Swift; Nicholas Beazley-Long
Journal:  Curr Opin Support Palliat Care       Date:  2018-06       Impact factor: 2.302

7.  Effects of peripheral inflammation on the blood-spinal cord barrier.

Authors:  Dimitris N Xanthos; Isabella Püngel; Gabriele Wunderbaldinger; Jürgen Sandkühler
Journal:  Mol Pain       Date:  2012-06-18       Impact factor: 3.395

8.  Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway.

Authors:  Margarita Calvo; Ning Zhu; John Grist; Zhenzhong Ma; Jeffrey A Loeb; David L H Bennett
Journal:  Glia       Date:  2011-01-06       Impact factor: 7.452

Review 9.  Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain.

Authors:  Knut Biber; Erik Boddeke
Journal:  Front Cell Neurosci       Date:  2014-08-07       Impact factor: 5.505

Review 10.  Neurovascular unit in chronic pain.

Authors:  Beatrice Mihaela Radu; Placido Bramanti; Francesco Osculati; Maria-Luisa Flonta; Mihai Radu; Giuseppe Bertini; Paolo Francesco Fabene
Journal:  Mediators Inflamm       Date:  2013-06-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.